Further studies on the erythrocyte anti-inflammatory assay.
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We report a case of combined contact and photocontact allergic dermatitis to etofenamate in Flogoprofen gel (Chiesi Wasserman, Barcelona, Spain). Patch test results were positive at the nonirradiated site, but there was a stronger reaction at the irradiated site with etofenamate 0.05% in petrolatum (pet.) at d2 and d4. The use frequent of topical agents containing etofenamate and sun exposure can result in a predisposition to contact photoallergy. Clinical findings caused by etofenamate are uncommon. Allergic contact dermatitis is the most common cutaneous reaction reported. In American studies observed, no reactions were observed to etofenamate in subjects with photosensitivity because it was not included in the series of antigens used in testing.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
2-(2-Hydroxyethoxy)ethyl-N-(a,a,a-trifluoro-m-tolyl)anthranilate (etofenamate, Rheumon Gel), a percutaneously active antirheumatic containing etofenamate as active principle has been subjected to clinical studies in both hospitalized and out-patients in various types of rheumatic disease. These trials included double-blind studies against placebo gel, controlled comparative studies against two topical commercial products (ointmentI: combination of 2-hydroxyethyl salicylate and p-menthan-3-ol; ointment II: 3,5-dioxo-1,2-diphenyl-4-n-butylpyrazolidine) and open trials for efficacy and tolerance. Of the 760 patients taking part in the trials, 556 were treated with Rheumon Gel.